DFE Pharma to Launch New Biopharma Excipient Solution
DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services.
DFE Pharma, a pharmaceutical excipient solutions company located in Germany, announced on April 21, 2021 that it has launched BioHale, a new product line aimed at addressing worldwide supply challenges for biopharmaceutical companies.
According to a company press release, the new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers with high quality excipient technology and services to advance therapeutic formulation.
“As a trusted solution provider and development partner to leading pharma brands, we are committed now to supporting customers in the formulation process for efficacious delivery of biologics,” said Bas van Driel, CEO of DFE Pharma, in the press release. “With the high purity and low endotoxin quality of BioHale excipients, combined with increased security of supply and stringent control over relevant supply chain processes, we can meet, if not exceed, the growing demands of new biopharma customers, as well as existing customers.”
Source: DFE
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
